FierceBiotech18h
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data
Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA ...
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...
SMALL CAP IDEA: Roquefort finds pharma diamonds in the rough
We find diamonds in the rough and we cut and finish them,' Roquefort boss Ajan Reginald says, summing up the company's ...
Arrowhead and Sarepta close $500 million licensing deal
PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR), currently trading at $20.24 and showing an 8% gain over the past week, has finalized its licensing and collaboration agreement ...
The EMBO Journal16h
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer
Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...
Earnings call transcript: Arrowhead Pharma misses Q1 2025 forecasts
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...
Understanding how twice-a-year Inclisiran therapy can transform cholesterol management, and the challenges facing adoption of this new drug
To understand the full scope of this medication -- its effectiveness, risks, and who stands to benefit the most -- ...